# NOW A POWERFUL NEW ALTERNATIVE FOR **GENITAL HERPES**

'Famvir' 250 mg Tablets 'Famvir' 125 mg Tablets famciclovir Prescribing Information Presentations 'Famvir Tiltab' 250 mg Tablets, PL 10592/0035, each Tablets, PL 10592/0035, each containing 250 mg famciclovir. 21 tablets: £10735, 15 tablets £76.68, 210 tablets: £10735, 15 tablets £76.68, 210 tablets: £1073.50. 'Famvir Tiltab' 125 mg Tablets, PL 10592/0055, each containing 125 mg famciclovir. 10 tablets: £25.56.

Uses Treatment of herpes zoster (shingles) infections and acute genital herpes infections. Famciclovir is the arral form of penciclovir converted in oral form of penciclovir, converted in the body to this active antiviral moiety. Dosage and administration Herpes zoster (shingles) infection Adults: One 250 mg tablet t.d.s. for 7 days. Treatment should be initiated as early Treatment should be initiated as early as possible in the course of the disease, promptly after diagnosis.

First-episode genital herpes infections Adults: One 250 mg tablet three times Adults: One 250 mg tablet three times daily for 5 days. Initiation of treatment is recommended as soon as possible after onset of lesions. Acute recurrent genital herpes infections Adults: One 125 mg tablet twice daily for 5 days. Initiation of treatment is recommended during the prodromal period or as soon as possible after onset of lesions. Elderly: As for adults unless renal function impaired. Renally impaired and renally impaired on haemodialysis: Reduced clearance of penciclovir related to reduced function; see Data Sheet for dosage modification. Hepatically impaired: No dosage modification required in well compensated hepatic impairment. *Children:* Data currently insufficient on safety and efficacy.

Contra-indication Known hypersensitivity Precautions Care in impaired renal function (see Data Sheet). **Drug interactions** No clinically significant pharmacokinetic interactions identified. Probenecid and other drugs affecting the kidney could affect plasma levels of penciclovir. Use in pregnancy and lactation Not to be used during pregnancy or lactation unless benefits outweigh risk. Oral penciclovir excreted in breast milk of

Adverse reactions Well tolerated in Adverse reactions Well tolerated in human studies. Generally mild or moderate headache and nausea reported in clinical trials and occurr at similar incidence to placetor.

Overdosage No acute overdosage reported. Symptomatic and supporti therapy as appropriate. Legal category POM.15.3.95. Based on "The Kiss," Auguste Rodin, 1886."



actating rats.



"Something for the next five years sir?"



SmithKline Beecham Pharmaceuticals Welwyn Garden City, Hertfordshire AL7 1EY. Presentation: Each 1 ml of 'Engerix B' hepatitis B vaccine (rby), PL 10592/0015, contains 20 micrograms of hepatitis B surface antigen protein, together with thiomersal 1:20,000. Pack of 1 (1 ml) prefilled syringe containing 20 micrograms, £12.13; pack of 10 (1 ml) prefilled syringes each containing 20 micrograms, £12.30; pack of 1 (1 ml) vial containing 20 micrograms, £11.95; pack of 3 (1 ml) vials each containing 20 micrograms, £35.85; pack of 10 (1 ml) vials, £119.50; pack of 1 paediatric (0.5 ml) vial containing 10 micrograms, £8.96.

**Uses:** Active immunisation against infections caused by hepatitis B virus.

Dosage and administration: For intramuscular use only. Shake well and inspect before use. Three doses should be given, the

second one month and the third six months after the initial do For more rapid immunisation the third dose can be given to months after the initial dose with a booster at 12 months. Adults and children over 12 years: 20 micrograms (1 ml) giv intramuscularly.

Neonates and children 12 years and under: 10 microgram (0.5 ml) given intramuscularly.

Administer in the deltoid region, though the antero-lateral thi is the preferred site for infants. Engerix B' should not administered in the buttock since this may result in low immune response. In neonates of HBsAg positive mothers, gi hepatitis B immunoglobulin at the same time as vaccine different sites within a few hours of birth.

intra-indications: Hypersensitivity to any component of the

'Engerix B' isn't just something for the weekend. It provides up to five years' protection against hepatitis B; which means you don't have to rely on your patients using a condom every time they have sex.

So who's at risk? People who are sexually active, either with multiple partners, or who travel abroad and have casual, unprotected sex.

The fact is hepatitis B can be contracted in the same way as AIDS, but it's 100 times more infectious. Worst still, it has been found in body fluids such as sweat, saliva, even tears.

It's quite reassuring to know then that, world-wide, 'Engerix B' has protected more people against the hepatitis B virus than any other vaccine.

You can order 'Engerix B' in pre-filled syringes, by calling SmithKline Beecham on 0181-913 4290. So, even if you can't prevent your patients from picking up every sexually transmitted disease, you can give them five years' protection against hepatitis B.

ceine. Severe febrile infections.

ecautions: Response may be impaired in renal dialysis patients those who are immunocompromised. Adrenaline 1:1000 ould be available in case of anaphylaxis. Use in pregnancy: see ita Sheet.

Iverse reactions: Mild transient local soreness, ervthema and furation at the injection site. Occasionally low grade fever, ılaise, fatigue, arthralgia, arthritis, myalgia, headache, dizziss, syncope, nausea, vomiting, diarrhoea, abdominal pain, nphadenopathy, abnormal liver function tests, rashes rarely th urticaria. Exceptionally, severe skin disorders such as vthema multiforme. Very rarely one week or more after injection, transient arthralgia, pruritus or urticaria, but no causal relationship established.

Neurological manifestations in temporal association with the vaccine, including very rarely paraesthesia and extremely rarely paralysis, neuropathy and neuritis (including Guillain-Barré syndrome, optic neuritis and multiple sclerosis). No causal relationship established.

Early onset allergic-type reactions reported rarely. Legal category POM. 11.8.94.

'Engerix B' is a trade mark.

© 1995 SmithKline Beecham Pharmaceuticals




0695 EB:AD/5/051

# Your resource for the latest information on **Sexually Transmitted Diseases**

Sexually Transmitted Diseases is your resource for the most current, comprehensive information available on all aspects of sexually transmitted disease. Its unique, multidisciplinary perspective provides insight into the latest advances in the field.

- Diagnosis and Treatment Etiology
- Pathology Epidemiology Microbiology
- Public Health and Behavior

Published bi-monthly, *Sexually Transmitted Diseases* brings you original articles on newly identified syndromes, new investigations into the mechanism of disease, descriptions of clinical experiences and reports on therapeutic trials. Features include notes from the CDC, NIH and ASHA, case reports and AVDA news.



**NO-RISK GUARANTEE!** If you're not completely satisfied, you may cancel your subscription at any time and receive a refund for all unmailed issues.

**SUBSCRIBE TODAY!** Call us today **TOLL FREE 1-800-777-2295** in the U.S. or **1-301-714-2300** outside the U.S. or FAX your order **1-301-824-7390** 

Published bi-monthly annual subscription rates: Individual \$135.00 (U.S.) - \$145.00 (Other countries) Institution \$187.00 (U.S.) - \$225.00 (Other countries)

PUBLISHED BY



227 East Washington Square Philadelphia, PA 19106-3780

# How do you...

Persuade a government to ban tobacco advertising?

Campaign against dumping of toxic waste?

#### Energise the fight against AIDS?

In The Fight for Public Health, Simon Chapman and Deborah Lupton show how lobbying through media advocacy can be a powerful tool in mobilising public support and getting public health legislation passed. Illustrated with photographs and crammed with compelling examples from around the world, this lively and entertaining guide:


- Describes what advocacy is
- Shows how public opinion has influenced public health policy in the past
- Includes an A-Z of strategies for gaining media attention.

"This splendid book moves the art of media advocacy a giant step forward. Chapman and Lupton's counsel leapfrogs continents; it will be as welcome and

counsel leapfrogs continent it will be as welcome and applicable in London and Washington as in Sydney."

Michael Pertschuk, Director, The Advocacy Institute, Washington, DC

ISBN 0-7279-0849-9 200-Pages - October 1994 UK £19.95; Overseas £22.00 (BMA members £18.95; £21.00) - **RM** 



#### ORDER FORM

Available from: BMJ Publishing Group, P.O. Box 295, London WC1H 9TE (Tel: 071-383-6185/6245), medical booksellers or the BMJ bookshop in BMA House

_copy/ies of
ALTH
Postcode
itish Medical Journal) & A/MASTERCARD
Exp
•

☐ Please send me a BMJ PUBLISHING GROUP CATALOGUE

#### STDs: Why Counsel?

Brief, effective approaches to counselling in busy clinical settings

#### 21 November 1995 at 9.30pm

at The Royal Society of Medicine

#### Workshop Convenors and Facilitators

Riva Millar, Aids Counselling Coordinator and Honorary Senior Lecturer, Royal Free Hospital and School of Medicine

Michael Waugh, Consultant Genito-Urinary Physician United Leeds Teaching Hospitals and President, International Union against the Venereal Diseases and Treponemotoses

#### **Objectives**

The overall objective of the day is to facilitate the effective management of Viral and other STDs in various clinical settings.

#### This includes:

- 1. Current diagnosis
- 2. Treatment options
- 3. Infectivity and relationships
- 4. Approaches to difficult problems

#### **Topics**

Policies and practice, The extent of the problem and Hepatitis, Genital Herpes, Genital Papilloma Virus infection, Chlamydial Infection and Pelvic inflammatory disease, The role of the GP, HIV and Women, HIV and the Gay man, Syphilis, approaches to counselling, recruiting into drug trials, summary and recommendations

#### 5 CME Credits

£50 Fellows, £80 for Non Fellows

Registration forms available from Mrs Alyson Ling at The Royal Society of Medicine 1 Wimpole Street, London, W1M 8AE Tel: 0171 290 2985 Fax 0171 290 2989


# **Baffled by statistics?**

All doctors and medical students need a basic understanding of the statistics presented in medical journals and at clinical meetings. **Statistics in Clinical Practice** is a practical, easy to read guide to demystifying statistics which will show you how to interpret data and present statistical information yourself.

- Covers all the basic principles including probability, making conclusions based on statistical results and summarising data.
- Contains realistic clinical examples.
- Assumes only a basic knowledge of mathematics.
- Includes useful questions and answer sections to test yourself.

ISBN 0 7279 0907 X 128 Pages 1995 UK £10.95; Overseas £12.95 (BMA members £9.95; £12.00)

Available from: BMJ Publishing Group P.O. Box 295, London WC1H 9TE Tel: 0171 383 6185/6245 Fax: 0171 383 6662



## NEW WARTICON CREAM



New Warticon Cream is the first ever podophyllotoxin cream for the self-treatment of genital warts.

The cream combines the well proven efficacy 1 and good tolerability 2 of podophyllotoxin in an easy to use formulation.

Men and women will find that new Warticon Cream, with its discreet tube and simple application, adds convenience and dignity to the self-treatment of genital warts. rtico cream

Podophyllotoxin 0.15% w/w

### The cream of self-treatment for genital warts

**Abbreviated Prescribing Information** 

Warticon Cream Presentation: White homogeneous cream containing 0.15% w/w podophyllotoxin. Uses: For the topical treatment of condyloma acuminata affecting the penis, and the female external genitalia. Dosage and Administration: The affected area should be thoroughly washed with soap and water, and dried prior to application. Using a fingertip, Warticon Cream is applied twice daily for 3 days using only enough cream to just cover each wart. The hands should be thoroughly washed after each application. Residual warts should be treated with further courses of twice daily applications for 3 days at weekly intervals, if necessary, for a total of 4 weeks of treatment. Where lesions are greater in area than 4cm² it is recommended that treatment takes place under the direct supervision of medical staff. Contraindications, Warnings etc: Open wounds, hypersensitivity to podophyllotoxin. Avoid contact with the eyes. In the event of the preparation entering the eye, the eye should be thoroughly bathed in water. Prolonged contact with healthy skin should be avoided, as the cream contains an active pharmaceutical substance that could be harmful to healthy skin. Side Effects: Local irritation

may occur on second or third day of application associated with the start of wart necrosis. In the majority of cases the reactions are mild (see Data Sheet). Use in Pregnancy: Do not use during pregnancy or lactation. Overdosage: There have been no reported overdosages with Warticon Crea No specific antidote is known. In the event of accidental ingestion give emetic or stomach washou Treatment should be symptomatic and in severe oral overdose ensure the airway is clear and give fluids, check and correct electrolyte balance, monitor blood gases and liver function. Blood count should be monitored for at least five days. Pharmaceutical Precautions: Product should be stored room temperature. Legal Category: POM. Package Quantities: Single tube containing 5g of Warti Cream. The pack also contains a mirror to facilitate accurate application. Basic NHS Price: Wartico Cream Sg £17.40. Product Licence Number: PL 3863/0010. Date of Preparation: March 1995. References: 1. Kinghorn, G. et al. International Journal of STD & AIDS 1993; 4: 194-199. 2. Strand, A. et al. 1995 In press